Cancer and Metastasis Reviews

, Volume 20, Issue 1–2, pp 51–56 | Cite as

Death Receptor Ligands, in Particular TRAIL, to Overcome Drug Resistance

  • S. de Jong
  • T. Timmer
  • F.J. Heijenbrok
  • E.G.E. de Vries


The efficacy of chemotherapeutic drugs is hampered by the occurrence of intrinsic and acquired drug resistance. A variety of mechanisms cause drug-resistance. A final common factor, however, is the reduced capacity of drug resistant cells to go into apoptosis following treatment with DNA damaging agents. This is due to defects in apoptotic pathways, for example, changes in p53. The presence of a common factor makes it of interest to search for ways that facilitate the cell to go into apoptosis following exposure to chemotherapeutic drugs. The death receptor ligands tumor necrosis factor (TNF), Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) are able to induce apoptosis by binding to their cell membrane receptors. Recombinant forms of these ligands are capable to potentiate the effect of chemotherapeutic drugs in vitro and in vivo in the animal model. Based on preclinical toxicity and activity profiling, especially TRAIL is considered to be of interest for clinical use. Systemic treatment of non-human primates with TRAIL did not result in acute toxicity. Animal studies demonstrated antitumor activity of TRAIL and potentiation of the chemotherapy efficacy by TRAIL. Phase 1 studies with TRAIL will therefore be initiated. As TRAIL is supposed to be non-toxic, it will be a major challenge to design surrogate end points to find the optimal dose in the clinic. In analogy to the herceptin therapy, it may be helpful to characterize the tumor of the patient. In addition, ex vivo exposure of the tumor may also be useful to select the proper ligand therapy for the individual patient. For optimal effect it is most likely that ligand therapy will be combined with chemotherapy, but even a combination of ligands for patient treatments can be envisioned. It is to be expected that smart, small molecules targeting these death receptors will be designed in order to lower toxicity and increase antitumor activity.

death receptor TRAIL drug resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941–2953, 1999Google Scholar
  2. 2.
    Ashkenazi A,Dixit VM: Death receptors: Signaling and modulation. Science 281: 1305–1308, 1998Google Scholar
  3. 3.
    Slamon DJ,Leyland-Jones B,Shak S,Fuchs H,Paton V,Bajamonde A,Fleming T,Eiermann W,Wolter J,Pegram M,Baselga J,Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 344: 783–792, 2001Google Scholar
  4. 4.
    Stephenson J: Researchers describe findings for targeted cancer therapies. JAMA 284: 293–295, 2000Google Scholar
  5. 5.
    Timmer T, de Vries EGE, de Jong S: Fas receptor-mediated apoptosis: A clinical application? J Pathol (accepted)Google Scholar
  6. 6.
    Walczak H,Miller RE,Ariail K,Gliniak B,Griffith TS,Kubin M,Chin W,Jones J,Woodward A,Le T,Smith C,Smolak P,Goodwin RG,Rauch CT,Schuh JC,Lynch DH: Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat Med 5: 157–163, 1999Google Scholar
  7. 7.
    Ashkenazi A,Pai RC,Fong S,Leung S,Lawrence DA,Marsters SA,Blackie C,Chang L,McMurtrey AE,Hebert A,DeForge L,Koumenis IL,Lewis D,Harris L,Bussiere J,Koeppen H,Shahrokh Z,Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155–162, 1999Google Scholar
  8. 8.
    Lawrence D,Shahrokh Z,Marsters S,Achilles K,Shih D,Mounho B,Hillan K,Totpal K,DeForge L,Schow P,Hooley J,Sherwood S,Pai R,Leung S,Khan L,Gliniak B,Bussiere J,Smith CA,Strom SS,Kelley S,Fox JA,Thomas D,Ashkenazi A: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383–385, 2001Google Scholar
  9. 9.
    Lacour S,Hammann A,Wotawa A,Corcos L,Solary E,Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61: 1645–1651, 2001Google Scholar
  10. 10.
    Nimmanapalli R,Porosnicu M,Nguyen D,Worthington E,O'Bryan E,Perkins C,Bhalla K: Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosisinducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7: 350–357, 2001Google Scholar
  11. 11.
    Joensuu H,Roberts PJ,Sarlomo-Rikala M,Andersson LC,Tervahartiala P,Tuveson D,Silberman S,Capdeville R,Dimitrijevic S,Druker B,Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052–1056, 2001Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • S. de Jong
    • 1
  • T. Timmer
    • 1
  • F.J. Heijenbrok
    • 1
  • E.G.E. de Vries
    • 1
  1. 1.Department of Medical OncologyUniversity Hospital GroningenThe Netherlands

Personalised recommendations